We are pleased to share the news of our strategic collaboration with BIOTON S.A. Together, we embark on a groundbreaking proof-of-concept project aimed at transdermal insulin delivery – a pioneering initiative set to make history.
BIOTON, the world’s top eight commercial manufacturers of recombinant human insulin, provides patients with safe and complete solutions for diabetes care. The company’s unparalleled expertise in insulin, combined with our patented transdermal technology, creates a synergy poised to revolutionize diabetes management.
We aim to provide a needle-free, effective, and achievable alternative route of drug administration to patients worldwide through the innovative transdermal delivery method. This collaboration represents a significant stride toward making healthcare more accessible and patient-friendly.
– The collaboration between our two companies from Poland demonstrates innovation which is on-going within Polish Biotech and MedTech. Most importantly, transdermal technology gives wider choices on drug delivery systems to our patients. Insulin is an excellent first candidate for this technology as we have significant experience in the area – says Jeremy L., CEO of Bioton.
– Not only will this improve the quality of life of millions of diabetes patients around the world, it will also inspire the pharmaceutical industry to develop similar alternatives in other therapeutic areas with our technology – adds Jan Henk Hendriks, CEO of Biotts.
